Search

Your search keyword '"Babu, K Govind"' showing total 11 results
Start Over Author "Babu, K Govind" Publisher medknow
11 results on '"Babu, K Govind"'

1. Indian clinical practice consensus guidelines for the management of very advanced head-and-neck squamous cell carcinoma: Update 2022

Author

Noronha, Vanita, primary, Prabhash, Kumar, additional, Babu, K Govind, additional, Chaturvedi, Pankaj, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K., additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Singhal, Manish, additional, Gairola, Munish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M., additional, Rao, Vishal, additional, Roshan, Vikas, additional, and Rath, G.K., additional

Published
2024
Full Text
View/download PDF

2. Indian clinical practice consensus guidelines for the management of hypopharyngeal cancer: Update 2022

Author

Babu, K Govind, primary, Prabhash, Kumar, additional, Chaturvedi, Pankaj, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K., additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Singhal, Manish, additional, Gairola, Munish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M., additional, Rao, Vishal, additional, Noronha, Vanita, additional, Roshan, Vikas, additional, and Rath, G. K., additional

Published
2024
Full Text
View/download PDF

3. Indian clinical practice consensus guidelines for the management of oral cavity cancer: Update 2022

Author

Chaturvedi, Pankaj, primary, Prabhash, Kumar, additional, Babu, K Govind, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K., additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Singhal, Manish, additional, Gairola, Munish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M, additional, Rao, Vishal, additional, Noronha, Vanita, additional, Roshan, Vikas, additional, and Rath, G.K., additional

Published
2024
Full Text
View/download PDF

4. Indian clinical practice consensus guidelines for the management of laryngeal cancer: Update 2022

Author

Singhal, Manish, primary, Prabhash, Kumar, additional, Babu, K. Govind, additional, Chaturvedi, Pankaj, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K., additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Gairola, Munish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M., additional, Rao, Vishal, additional, Noronha, Vanita, additional, Roshan, Vikas, additional, and Rath, G. K., additional

Published
2024
Full Text
View/download PDF

6. Indian clinical practice consensus guidelines for the management of oropharyngeal cancer: Update 2022

Author

Noronha, Vanita, primary, Prabhash, Kumar, additional, Babu, K Govind, additional, Chaturvedi, Pankaj, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K, additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Singhal, Manish, additional, Gairola, Munish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M, additional, Rao, Vishal, additional, Roshan, Vikas, additional, and Rath, G.K., additional

Published
2024
Full Text
View/download PDF

7. Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer: Update 2022

Author

Gairola, Munish, primary, Prabhash, Kumar, additional, Babu, K Govind, additional, Chaturvedi, Pankaj, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K., additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Singhal, Manish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M., additional, Rao, Vishal, additional, Noronha, Vanita, additional, Roshan, Vikas, additional, and Rath, G.K., additional

Published
2024
Full Text
View/download PDF

8. Introduction to Indian clinical practice consensus guidelines for the management of squamous cell carcinoma the head-and-neck: Update 2022

Author

Noronha, Vanita, primary, Prabhash, Kumar, additional, Babu, K Govind, additional, Chaturvedi, Pankaj, additional, Kuriakose, Moni, additional, Birur, Praveen, additional, Anand, Anil K., additional, Kaushal, Ashish, additional, Mahajan, Abhishek, additional, Syiemlieh, Judita, additional, Singhal, Manish, additional, Gairola, Munish, additional, Ramachandra, Prakash, additional, Goyal, Sumit, additional, John, Subashini, additional, Nayyar, Rohit, additional, Patil, Vijay M., additional, Rao, Vishal, additional, Roshan, Vikas, additional, Rath, G. K., additional, Singh, Jaskaran, additional, and Bhardwaj, Bhanu, additional

Published
2024
Full Text
View/download PDF

9. Primary cutaneous B-cell lymphoma: A single-center 5-year experience

Author

Nikita J Mulchandani, Deepak Koppaka, Suresh Babu, Babu K Govind, K N Lokesh, Vikas Asati, K C Lakshmaiah, Abhishek Anand, Suma Narayana Mysore, D. Lokanatha, A H Rudresh, L K Rajeev, and Linu Abraham Jacob

Subjects
Adult, Male, medicine.medical_specialty, Lymphoma, B-Cell, Skin Neoplasms, Adolescent, medicine.medical_treatment, Cutaneous B-cell lymphoma, CHOP, Single Center, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Immunophenotyping, immune system diseases, hemic and lymphatic diseases, medicine, Humans, Retrospective Studies, Chemotherapy, business.industry, Middle Aged, medicine.disease, Dermatology, Lymphoma, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Scalp, Female, Rituximab, business, medicine.drug
Abstract

BACKGROUND: Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity. MATERIALS AND METHODS: Patients diagnosed with PCBCL between January 2012 and July 2017 at our center were retrospectively analyzed. RESULTS: Eight patients of PCBCL were diagnosed. Three patients (37.5%) were males while 5 patients (62.5%) were females. The median age at diagnosis was 45 years (range, 18–60 years). Scalp was the most common site of involvement (50% of the patients). Diffuse large B-cell lymphoma (DLBCL) was the most common histology (63%), with leg-type DLBCL diagnosed in 1 patient. Two patients had primary cutaneous follicle center lymphoma, whereas the remaining 1 patient had precursor B-lymphoblastic lymphoma. All 5 DLBCL cases were treated with CHOP chemotherapy, and rituximab was given to 3 patients. Of the primary cutaneous follicle center lymphomas, 1 patient with stage II disease was treated with CHOP and is alive without recurrence for the past 5 years, whereas the other patient is on observation alone. The patient with precursor B-lymphoblastic lymphoma was started on MCP-841 protocol; however, the patient did not complete the treatment and died after 11 months. CONCLUSIONS: PCBCL is a heterogeneous group of diseases and dividing them into subtypes, based on morphology and immunophenotype, has therapeutic implications.

Published
2018
Full Text
View/download PDF

11. Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study.

Author

Kamath MP, Lakshmaiah KC, Babu KG, Loknatha D, Jacob LA, and Babu SM

Abstract

Background: The incidence of lung cancer is rising in developing countries like India. Due to unaffordability among the low socioeconomic status (SES) patients, there is a significant delay in seeking appropriate medical treatment due to which a high proportion of patients present in an advanced/metastatic stage and the outcomes are poor., Objective: In this study, we studied the progression-free survival (PFS) and the pharmacoeconomic benefits with the cisplatin plus etoposide (EtoP) chemo regimen and compared it with the current generation chemo regimen., Materials and Methods: We performed a retrospective analysis of metastatic nonsmall cell lung cancer patients who received one or more cycles of platinum-based chemotherapy between 2011 and 2014., Results: Of the 304 patients, 56.6% of the patients were of the low SES. Of the low socioeconomic group patients, 67.45% and 31.4% received etoposide and paclitaxel platinum doublet combination regimen as first line, respectively. The mean PFS with the etoposide, paclitaxel, pemetrexed, and gemcitabine platinum-based doublet regimens were 9.35, 10, 10.76, and 9.83 months, respectively. Kaplan-Meier survival curve analysis showed a statistically significant initial survival with the first line EtoP cisplatin regimen for the initial 6 months of starting chemotherapy in comparison with the other regimens., Conclusions: This study showed a substantial pharmacoeconomic benefit with the cisplatin and etoposide chemo regimen in the lower socioeconomic group of patients. We believe that this is the first pharmacoeconomic study on metastatic non small cell lung treatment of great relevance to countries with limited resources.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results